Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Orexo on bond issue
Mandate

Vinge advised Orexo on bond issue

May 05, 2014

Orexo AB (publ) (NASDAQ OMX Stockholm) has issued a four-year senior unsecured bond loan of SEK 500 million, with the possibility to issue a further SEK 500 million of bonds. The bonds are to be listed on NASDAQ OMX Stockholm.                      

Vinge acted as legal adviser to Orexo. The Vinge team included partners Erik Sjöman (capital markets and public M&A) and Henrik Ossborn (banking & finance), and associates Christian Lindhé (capital markets and public M&A) and Fredrik Christiansson (banking & finance).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026